Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: A clinical review

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 6, 2009, Pages 618-628

  Pollack, Seth M ^a   O'Connor Jr , Thomas P ^a   Hashash, Jana ^a   Tabbara, Imad A ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hematopoietic; Nonmyeloablative; Reduced intensity; Transplant

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BUSULFAN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; FLUDARABINE; IDARUBICIN; IMATINIB; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIMICROBIAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DONOR; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG WITHDRAWAL; HODGKIN DISEASE; HUMAN; IMMUNE SYSTEM; INTERMETHOD COMPARISON; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PANCYTOPENIA; PROSPECTIVE STUDY; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; REVIEW; SOLID TUMOR; T LYMPHOCYTE; TREATMENT WITHDRAWAL; VEIN OCCLUSION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BLOOD DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT;

GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 73349090585     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31817f9de1     Document Type: Review

References (99)

1. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graftversus- host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
2. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86: 2041-2050.
3. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553-1562.
4. Tabbara IA, Ingram RM. Nonmyeloablative therapy and allogeneic tranplantation. Exp Hematol. 2003;31:559-566.
5. Storb R, Raff RF, Appelbaum FR, et al. Comparison of fractionated to single-dose total body irrasiation in conditioning canine littermates for DLAidentical marrow grafts. Blood. 1989;74:1139-1143.
6. Yu C, Sandmaier BM, Deeg HJ, et al. What role for radiation in novel nonmyeloablative transplant regimen for DLA-identical marrow grafts: Immunosuppression verson 'creation' of marrow space? Blood. 1997;90(suppl 1):1608.
7. Yu C, Storb R, Mathey B, et al. DLA identical bone marrow grafts after low dose total body irradiation effects of high-dose corticosteroids and cyclosporin on engraftment. Blood. 1995;86:4376-4381.
8. Storb R, Yu C, Wagner J, et al. Stable mixed hematopoietic chimerism in DLA Identical littermate dogsgiven sublethal total body irradiation before pharmacological immunosuppression after marrow tranplantation. Blood. 1997;89:3048-3054.
9. Yu C, Seidel K, Nash RA, et al. Synergism between mycophenelate mofetil and cyclosporin in preventing graft versus host disease among lethally irradiated dogs given DLA- non identical unrelated marrow grafts. Blood. 1998;91:2581-2587.
10. Stewart FM, Zhong S, Wuu J, et al. Lymphohematopoietic engraftment in minimally myeloablated host. Blood. 1998;91:3681-3687.
11. McSweeney PA, Niederwiesser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97: 3390-3400. .
12. Gratwohl A, Baldomero H, Frauendorfer K, et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant. 2007;39:71-87.
13. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993-2003. (Pubitemid 46211379)
14. Maris M, Boeckh M, Storer B, et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol. 2003;31:941-952. (Pubitemid 37211379)
15. Valcarcel D, Martino R, Sureda A, et al. Conventional versus reducedintensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol. 2005;74:144-151.
16. Gomez-Nunez M, Martino R, Caballero MD, et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. Bone Marrow Transplant. 2004;33:477-482.
17. Corradini P, Zallio F, Mariotti J, et al. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol. 2005;23:6690-6698.
18. Slavin S, Nagler A, Naperstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
19. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810-1814.
20. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 89:4531-4536.
21. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.
22. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell tranplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
23. Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003;101:441-445.
24. Uzunel M, Mattsson J, Brune M, et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood. 2003; 101:469-472.
25. Kerbauy FR, Storb R, Hegenbart U, et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low dose radiation-based conditioning for treatment of CML. Leukemia. 2005;19:990-997.
26. Kebriaei P, Detry MA, Giralt S, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood. 2007;110:3456-3462.
27. Sloand E, Childs RW, Solomon S, et al. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplant. 2003;32:897-901.
28. Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl mutation-realated imatinib failure. Blood. 2006;108: 1421-1423.
29. Serrano J, Roman J, Sanchez J. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of 210BCR-ABL and 190BCR-ABL after allogneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190 BCR-ABL detection precede cytogenetic relapse. Blood. 2000;95:2659-2665.
30. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002;100:1590-1595. (Pubitemid 34925133)
31. DeAngelo DJ, Hochberg EP, Alyea EP, et al. Extended follow-up of patients treated with imatinib mesylate (Gleevac) for chronic myelongenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004;10:5065-5071.
32. Olavarria E, Ottman OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2003;17:1707-1712.
33. Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase ii open-label multicenter study. J Clin Oncol. 2005;23: 7583-7593.
34. Jabbour E, Cortes J, Kantarjian H, et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007;110:340-344.
35. Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5675-5687.
36. Stelljes M, Bornhauser M, Kroger M, et al. Conditioning with 8 Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood. 2005;106:3314-3321.
37. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304-2312.
38. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20:128-135.
39. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-boday, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;444-453.
40. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865-872.
41. Malladi RK, Peniket AJ, Norton AE, et al. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. Eur J Haematol. 2004;73:85-92.
42. Mohty M, de Lavallade H, Ladaique P, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia. 2005;19:916-920. (Pubitemid 40862000)
43. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005; 23:9387-9393.
44. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616-1623.
45. Gutierrez-Aguirre CH, Cantú-Rodríguez OG, Gonzalez-Llano O, et al. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology. 2007;12:193-197.
46. Feinstein LC, Sandmaier BM, Hegenbart U, et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukemia in first complete remission. Br J Haematol. 2003;120:281-288.
47. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007;21:2316-2323.
48. Kebriaei P, Kline J, Stock W, et al. Impact of disease burden at time of allogeic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005;35:965-970.
49. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2007;24:444-453.
50. Shimoni A, Harden I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced intensity conditioning: the role of dose-intensity. Leukemia. 2006;20:322-328.
51. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23:3819-3829.
52. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation study. Blood. 2006;107:1724-1730.
53. Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood. 2004;104:2600-2602.
54. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versusleukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003;21:2747-2753.
55. Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graftversus- leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia. 2003; 17:841-848.
56. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32:28-35.
57. Brown JR, Kim HT, Li S, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006; 12:1056-1064.
58. Arnold R, Massenkeil G, Bornhauser M, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia. 2002;16:2423-2428.
59. Martino R, Giralt S, Caballero MD, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica. 2003;88:555-560.
60. Massenkeil G, Nagy M, Le Coutre P, et al. Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD. Hematol J. 2004;5:395-402.
61. Escalon MP, Champlin RE, Saliba RM, et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol. 2004;22:2419 -2423.
62. a. Morris E, Thomson K, Craddock C, et al. Outcomes after Alemtuzumabcontaining reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865-3871.
63. Khouri I, Champlin R. Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol. 2004;31:22-26.
64. Vigouroux S, Michallet M, Porcher R, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica. 2007;92: 627-634.
65. Khouri IF, Lee MS, Saliba RM, et al. Nonablative stem-cell transplantation for advanced/recurrent mantle cell lymphoma. J Clin Oncol. 2003;21:4407-4412.
66. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535-3542.
67. Glass B, Nickelsen M, Dreger P, et al. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect. Bone Marrow Transplant. 2004;34:391-397.
68. Rodriguez R, Nadamanee A, Smith RN, et al. Comparison of reducedintensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006; 12:1326-1334.
69. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression- free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918-3927.
70. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant- related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005;35:943-951.
71. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus- Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365:1934-1942.
72. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105:4532-4539. (Pubitemid 40720805)
73. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447-3454.
74. Shimazaki C, Fujii H, Yoshida T, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group. Int J Hematol. 2005;81:342-348.
75. Carella AM, Beltrami G, Corsetti MT, et al. A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong antimyeloma activity. Haematologica. 2004;89:1534-1536.
76. Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002;20:1295-1303.
77. Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003;21:73-80.
78. Shaw BE, Peggs K, Bird JM, et al. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. Br J Haematol. 2003; 123:886-895.
79. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110-1120.
80. Garban F, Attal M, Michallet M, et al. prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tanem autologous stem cell transplantation (IFM99-04 trial) in high risk de novo multiple myeloma. Blood. 2006;107:3474-3480.
81. Childs RW, Clave E, Tisdale J, et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor- cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol. 1999;17:2044-2049.
82. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
83. Artz AS, Van Besien K, Zimmerman T, et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: the University of Chicago experience. Bone Marrow Transplant. 2005;35:253-260.
84. Morecki S, Yacovlev E, Diab A, et al. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res. 1998;58:3891-3895.
85. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence of a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88:1501-1508.
86. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16:986-993.
87. Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004;22:3886-3892.
88. Carella AM, Beltrami G, Corsetti MT, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet. 2005;366:318-320.
89. Kanda Y, Komatsu Y, Akahane M, et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation. 2005;79:821-827.
90. Takahashi T, Omuro Y, Matsumoto G, et al. Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer. Pancreas. 2004;28:e65-e69.
91. Ueno NT, Cheng YC, Rondon G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003;102:3829-3836.
92. Hentschke P, Barkholt L, Uzunel M, et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal cell and colon carcinoma. Bone Marrow Transplant. 2003;31:253-261.
93. Blaise D, Bay JO, Faucher C, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood. 2004;103:435-441.
94. Khouri I, Saliba R, Hosing C, et al. Autologous stem cell versus nonmyeloablative allogeneic transplantation after high dose rituximab containing conditioning regimens for relapsed chemosensitive lymphoma. Blood. 2005;106: 48a.
95. Marris MB, Sandmaier BM, Storer B, et al. Allogeneic hematopoietic stem cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma. Blood. 2005;106:329a.
96. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234-13231
97. Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia. 2006;20:1690-1700. (Pubitemid 44590958)
98. Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings at the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001; 473-485.
99. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103:1548-1556.